A Randomized, Double-blind Study to Demonstrate Pharmacokinetic Similarity, and Evaluate Safety, Immunogenicity, Pharmacodynamics, and Clinical Effects Between ABP 692 and Ocrevus® (Ocrelizumab) in Subjects With Relapsing-remitting Multiple Sclerosis
A Randomized, Double-blind Study to Demonstrate Pharmacokinetic Similarity, and Evaluate Safety, Immunogenicity, Pharmacodynamics, and Clinical Effects Between ABP 692 and Ocrevus® (Ocrelizumab) in Subjects With Relapsing-remitting Multiple Sclerosis
The Main objectives of the study are to demonstrate pharmacokinetic (PK) similarity between ABP 692 and ocrelizumab (US), as well as between ABP 692 and ocrelizumab (EU).
Inclusion Criteria:
Exclusion Criteria:
Carlsbad, California 92011, United States
Chicago, Illinois 60612-3841, United States
Farmington, Michigan 48334-2979, United States
Nîmes, 30029, France
Regensburg, 93059, Germany
Naples, 80138, Italy
Barcelona, 08036, Spain
Dénia, 03700, Spain
Malag, 29016, Spain
Valencia, 46026, Spain